Prof. Dr. Xiwen Li received his Ph.D. in Pharmacognosy from the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a postdoctoral fellow at Tsinghua University and the University of Macau. He is a researcher, doctoral supervisor, and deputy director of the Center for Pharmacognosy Research at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. He is mainly engaged in molecular identification and quantification of Chinese herbal medicines, herbal medicine cultivation, and genomic selection breeding. As the person in charge, he presided over more than 20 projects including the National Key R&D Program and the National Natural Science Foundation, and won one National Science and Technology Progress Award, three provincial and ministerial first prizes, and one first prize for international contribution to traditional Chinese medicine. He was selected into the top 2% of the world’s top scientists for three consecutive years. He has published more than 190 papers in domestic and foreign academic journals such as BiolREV, Mol Plant, and Science China Life Sciences. He is currently the deputy editor-in-chief of the SCI journal Mitochondrial DNA Part B, and an editorial board member or young editorial board member of journals such as APSB, CHM, CJNM, Acta Pharmaceutica Sinica, World Chinese Medicine, and Modern Chinese Medicine.
Prof. Dr. Xiwen Li received his Ph.D. in Pharmacognosy from the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a postdoctoral fellow at Tsinghua University and the University of Macau. He is a researcher, doctoral supervisor, and deputy director of the Center for Pharmacognosy Research at the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences. He is mainly engaged in molecular identification and quantification of Chinese herbal medicines, herbal medicine cultivation, and genomic selection breeding. As the person in charge, he presided over more than 20 projects including the National Key R&D Program and the National Natural Science Foundation, and won one National Science and Technology Progress Award, three provincial and ministerial first prizes, and one first prize for international contribution to traditional Chinese medicine. He was selected into the top 2% of the world’s top scientists for three consecutive years. He has published more than 190 papers in domestic and foreign academic journals such as BiolREV, Mol Plant, and Science China Life Sciences. He is currently the deputy editor-in-chief of the SCI journal Mitochondrial DNA Part B, and an editorial board member or young editorial board member of journals such as APSB, CHM, CJNM, Acta Pharmaceutica Sinica, World Chinese Medicine, and Modern Chinese Medicine.